Bay Labs Announces Collaboration with Edwards Lifesciences to Utilize AI Software to Improve Heart Disease Detection
Summary
SAN FRANCISCO--( BUSINESS WIRE )-- Bay Labs , a medical technology company at the forefront of applying artificial intelligence (AI) to cardiovascular imaging, announced today a collaboration with Edwards Lifesciences focused on improving the detection of heart disease.The companies believe that incorporating these and future algorithms into clinical practice could help drive quality improvement and potentially increase accurate heart disease detection.“Working with Edwards to deploy Bay Labs’ AI software with deep learning technology into clinical settings has the potential to derive quality improvements and to increase the accuracy of timely heart disease detection.”The CardioCare program combines clinical consulting expertise with a cloud-based platform to facilitate in the identification, referral, and care pathway management of patients with structural heart disease.Founded in 2013, Bay Labs applies artificial intelligence to cardiovascular imaging, and its deep learning technology is designed to help medical professionals of all skill levels perform and interpret high-quality echocardiography to ultimately benefit their patients.